GU Cancers 2020 | Daniel Petrylak: GU 2020 prostate picks
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses his research highlights from the 2020 ASCO GU meeting. Specifically mentioned was the combination of olaparib and cediranib for castrate-resistant prostate cancer and the COSMIC study, which investigated the combination of atezolizumab and cabozantinib for prostate cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up